Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
McNeil JJ, Nelson MR, Woods RL, et al.; for the ASPREE Investigator Group
N Engl J Med. 2018;379:1519-28
Leggi
Breaking news
Impact of maternal income on the risk of gestational diabetes mellitus in primiparous women
Rönö K, Masalin S, Kautiainen H, et al.
Diabet Med. Pub online 11 October 2018
Leggi
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil JJ, Wolfe R, Woods RL, et al.; for the ASPREE Investigator Group
N Engl J Med. 2018;379:1509-18
Leggi
Monotherapy laser photocoagulation for diabetic macular oedema
Jorge EC, Jorge EN, Botelho M, et al.
Cochrane Database Syst Rev. Pub. online 15 October 2018
Leggi
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes
Montvida O, Green JB, Atherton J, et al.
Diabet Med. Pub. online 10 October 2018
Leggi
Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
Liu Z, Dumville JC, Hinchliffe RJ, et al.
Cochrane Database Syst Rev. Pub. online 17 October 2018
Leggi
Twice the benefits with twincretins?
Stumvoll M, Tschöp M
The Lancet. Pub. online October 4, 2018
Leggi
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias JP, Nauck MA, Van J, et al.
The Lancet. Pub. online October 4, 2018
Leggi
HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
Mafham M, Preiss D
The Lancet. Pub. online October 2, 2018
Leggi
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Bohula EA, Scirica BM, Inzucchi SE, et al.
The Lancet. Pub. online October 4, 2018
Leggi